BioPharmSignal logoBioPharmSignal

Biotech News

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

Adaptive Biotechnologies (ADPT)Adaptive BiotechnologiesEarnings

SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial

Open original release

Related news

ADPTAdaptive Biotechnologies2026-05-05 20:05 EST

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

ICCMIceCure Medical2026-05-06 12:30 EST

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

IRIXIRIDEX2026-05-05 20:05 EST

Iridex to Report First Quarter 2026 Financial Results on May 19, 2026

CVRXCVRx2026-04-27 20:30 EST

CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

OMOutset Medical2026-04-27 20:05 EST

Outset Medical to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026

TMCITreace Medical Concepts2026-04-24 11:05 EST

Treace to Report First Quarter 2026 Financial Results on May 8, 2026

RXSTRxSight2026-04-22 20:10 EST

RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6

SGHTSight Sciences2026-04-21 20:05 EST

Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026

XTNTXtant Medical2026-05-07 12:00 EST

Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026

HYPRHyperfine2026-04-28 20:05 EST

Hyperfine, Inc. to Announce First Quarter 2026 Financial Results on May 12, 2026

View all latest news

Adaptive Biotechnologies

Adaptive Biotechnologies is a diagnostics and immune-profiling company focused on using immune-sequencing and molecular data to reveal disease signals. Its business is more about immune measurement than classic drug development.

Recent company news

ADPTAdaptive Biotechnologies2026-05-29 11:30 EST

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

ADPTAdaptive Biotechnologies2026-05-05 20:05 EST

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

ADPTAdaptive Biotechnologies2026-04-15 20:05 EST

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

ADPTAdaptive Biotechnologies2026-02-05 21:05 EST

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

ADPTAdaptive Biotechnologies2026-01-27 21:05 EST

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Stock data

Close
22.54 USD
Market cap
2.42B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States